Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Work In Process (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Work In Process for 7 consecutive years, with $13.8 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Work In Process rose 15.0% year-over-year to $13.8 million, compared with a TTM value of $13.8 million through Mar 2025, up 15.0%, and an annual FY2024 reading of $10.9 million, up 12.37% over the prior year.
  • Work In Process was $13.8 million for Q1 2025 at Neurocrine Biosciences, up from $10.9 million in the prior quarter.
  • Across five years, Work In Process topped out at $13.8 million in Q1 2025 and bottomed at $9.7 million in Q4 2023.
  • Average Work In Process over 3 years is $11.5 million, with a median of $11.4 million recorded in 2024.
  • The sharpest move saw Work In Process increased 12.37% in 2024, then grew 15.0% in 2025.
  • Year by year, Work In Process stood at $9.7 million in 2023, then rose by 12.37% to $10.9 million in 2024, then rose by 26.61% to $13.8 million in 2025.
  • Business Quant data shows Work In Process for NBIX at $13.8 million in Q1 2025, $10.9 million in Q4 2024, and $10.6 million in Q3 2024.